BRCA-mutated prostate cancer

J&J joins PARP rivals with narrow FDA clearance in prostate cancer
BioPharma Dive
Mon, 08/14/23 - 10:18 am
JNJ
Akeega
BRCA-mutated prostate cancer
PARP inhibitors
FDA
AstraZeneca, Merck notch another major Lynparza trial win — this time in pancreatic cancer
Endpoints
Tue, 02/26/19 - 09:34 am
AstraZeneca
Merck
pancreatic cancer
clinical trials
BRCA-mutated prostate cancer